October 16, 2019

CORRECTED: Ohio counties can’t seek $800 million in 'future' opioid damages

Oct 16 - (This story has been updated to correct the first name of David Cohen, the special master.)
October 16, 2019

Opioid settlement talks broaden ahead of 1st federal trial

Efforts to settle thousands of lawsuits related to the nation's opioid epidemic intensified Wednesday ahead of the scheduled start of arguments in the first federal trial over the crisis.
October 16, 2019

As counties slam drug companies, landmark federal opioid trial embarks on jury selection

CLEVELAND – Jury selection is scheduled to begin Wednesday in the first federal trial over the opioid epidemic.
October 15, 2019

Your Guide To The Massive (And Massively Complex) Opioid Litigation

In less than a week, a landmark battle over who bears responsibility for the U.S. opioid crisis will begin in federal court.
October 15, 2019

Democratic debate: Here's what the candidates had to say about Ohio

WESTERVILLE - Democrats took the stage in the Columbus suburb of Westerville Tuesday. But did they study up on Ohio?
October 15, 2019

Local businesses work together to combat Ohio's growing opioid crisis

Treatment facilities and employers are working to tackle the opioid epidemic in central Ohio, which has been particularly hard hit by the growing national crisis.
October 14, 2019

Court Denies Ohio’s Attempt to Stop Cleveland Opioid Trial

A federal appeals court has denied an effort led by Ohio’s attorney general to stop a bellwether trial over the opioid crisis from starting this month in Cleveland.
October 14, 2019

Johnson & Johnson Settles Ohio Opioid Cases for $20.4 Million to Avoid Federal Trial Does this mean anything for the pharmaceutical giant's long-term outlook?

Johnson & Johnson (NYSE:JNJ) made news in late August when a state judge in Oklahoma found the pharmaceutical giant guilty of deceptively marketing its opioid medications to customers. The verdict was seen as a hallmark ruling for the pharmaceutical sector. That, combined with Purdue Pharma declaring bankruptcy due to the $12 billion settlement it's facing, has many investors worried the door has been opened to similar, perhaps much larger, fines for other companies in the opioid market.